Search our Database of Scientific Publications and Authors

I’m looking for a

    847 results match your criteria Lupus Erythematosus Subacute Cutaneous

    1 OF 17

    Autoantibody profile and clinical patterns in 619 Italian patients with cutaneous lupus erythematosus.
    J Eur Acad Dermatol Venereol 2018 Jun 20. Epub 2018 Jun 20.
    Department of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Florence, Italy.
    Background: Anti-nuclear antibodies (ANA), anti-extractable nuclear antigens (ENA) and anti-dsDNA antibodies are often associated with cutaneous lupus erythematosus (CLE), with variable frequency depending on skin subtype. However, specific data based on large case-series on the pathogenetic, diagnostic, and prognostic meaning of such autoantibodies are still lacking.

    Objective: To characterize the correlations between CLE subtypes as well as LE-non specific skin lesions and their autoantibody pattern. Read More

    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-Like Lupus Erythematosus.
    J Clin Rheumatol 2018 Jun 15. Epub 2018 Jun 15.
    From the Division of Dermatology, Department of Internal Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
    Background/objective: Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN)-like lupus erythematosus is a hyperacute and life-threatening form of cutaneous lupus erythematosus. Because of its rarity, little is known about this entity. We aimed to evaluate the clinical characteristics, laboratory findings, systemic manifestations, treatments, and outcome of SJS/ TEN-like lupus erythematosus. Read More

    Drug-induced lupus erythematosus: an update on drugs and mechanisms.
    Curr Opin Rheumatol 2018 Jun 4. Epub 2018 Jun 4.
    Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
    Purpose Of Review: Rapid introduction of newly developed drugs in the absence of clear understanding of the pathophysiologic mechanisms behind drug-induced lupus erythematosus (DILE) can sometimes make DILE difficult to recognize in clinical practice. The purpose of this review is to summarize drugs most recently reported to be involved in DILE and discuss the current landscape of diverse mechanisms involved.

    Recent Findings: A large number of proton pump inhibitor (PPI)-induced subacute cutaneous lupus erythematosus cases have been reported, suggesting a shift over time in the spectrum of drugs implicated in DILE. Read More

    Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark.
    Lupus 2018 Jan 1:961203318777103. Epub 2018 Jan 1.
    2 OPEN - Open Patient data Explorative Network, Department of Clinical Research, University of Southern Denmark, Denmark.
    Objectives The objectives of this paper are to describe the epidemiology of cutaneous lupus erythematosus (CLE) and its subtypes in Denmark, and to investigate the probability of receiving a subsequent diagnosis of systemic lupus erythematosus (SLE) and the related time course. Methods A nationwide registry-based cohort study was conducted in Denmark based on data from the Danish National Patient Registry from 1998 to 2013 using International Classification of Diseases, Revision 10. Results We identified 2380 patients with CLE. Read More

    Drug-induced Subacute Cutaneous Lupus Erythematosus Caused by a Topical Beta Blocker - Timolol.
    Acta Dermatovenerol Croat 2018 Apr;26(1):44-47
    Monika Bilewicz-Stebel, MD Department of Internal Medicine, Dermatology and Allergology, Curie-Skłodowskiej 10, 41-800 Zabrze, Poland, School of Public Health Medical University of Silesia in Katowice 40-027 Katowice, Poland;
    Drug-induced lupus erythematosus (DI-LE) is an autoimmune condition secondary to a recent pharmacological intervention. There are no established specific diagnostic criteria for DI-LE, and the disease is recognized based on the medical history of the patient. Typically, the onset is closely related to a recent drug exposure, and the disease terminates after discontinuation of the inducing factor. Read More

    Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study.
    Postepy Dermatol Alergol 2018 Apr 24;35(2):192-198. Epub 2018 Apr 24.
    Department of Dermatology, University of Rzeszow, Rzeszow, Poland.
    Introduction: Due to a wide array of dermatologic manifestations, assessment of disease severity in cutaneous lupus erythematosus (CLE) remains challenging. Given a need for some standardization in this field, we conducted a worldwide questionnaire-based study among physicians experienced in CLE management.

    Aim: We asked about CLE assessment, their prophylactic measures advised to patients, and treatment recommendations. Read More

    CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study.
    Arch Dermatol Res 2018 May 4. Epub 2018 May 4.
    Department of Dermatology, Medical University of Graz, Auenbruggerplatz 8, 8036, Graz, Austria.
    Serum levels of the IFN-regulated cytokine CXCL13 have been found to correlate with SLEDAI and renal involvement in systemic lupus erythematosus. This study investigates whether CXCL13 can also be a marker of disease activity in patients with subacute cutaneous or chronic cutaneous lupus erythematosus (SCLE, CCLE). We analysed CXCL13 levels in 60 patients' sera (18 SLE, 19 SCLE, 23 CCLE) at five time points within 1 year and correlated these levels with disease activity scores and laboratory markers. Read More

    Coexistence of chronic cutaneous lupus erythematosus and frontal fibrosing alopecia.
    An Bras Dermatol 2018 Mar;93(2):274-276
    Department of Dermatology, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
    Lupus erythemathosus is a chronic, relapsing disease with acute, subacute, and chronic lesions. Effluvium telogen occurs in the setting of systemic activity of the disease, and cicatricial alopecia results from discoid lesionsin on the scalp. Other types of alopecia, like alopecia areata, may rarely be found in lupus. Read More

    Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Lupus 2018 Jan 1:961203318768877. Epub 2018 Jan 1.
    1 Autoimmune Diseases Research Unit, Department of Internal Medicine, Biocruces, 16494 Hospital Universitario Cruces , UPV/EHU Bizkaia, The Basque Country, Spain.
    Aim The aim of this study was to evaluate the clinical response to combined therapy with hydroxychloroquine and mepacrine in patients with systemic lupus erythematosus and refractory joint and/or skin disease. Methods Mepacrine was added to 46 systemic lupus erythematosus patients unresponsive to treatment with the following drug combinations: hydroxychloroquine + prednisone + immunosuppressive drugs ( n = 24), hydroxychloroquine + prednisone ( n = 16), hydroxychloroquine + prednisone + retinoids ( n = 2), hydroxychloroquine alone ( n = 1), hydroxychloroquine + one immunosuppressive drug ( n = 1), hydroxychloroquine + prednisone + one immunosuppressive drug + belimumab ( n = 1) or hydroxychloroquine + prednisone + belimumab ( n = 1). The outcome variable was the clinical response, either complete or partial, based on clinical judgement. Read More

    The devil's in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda.
    Lupus 2018 Jul 9;27(8):1383-1386. Epub 2018 Apr 9.
    1 Division of Rheumatology, University of Michigan Medical School, USA.
    A 29-year-old woman with a 1.5 year history of photosensitive skin lesions on her hands presented with a malar rash, bullous lesions on her hands, and was diagnosed with subacute lupus erythematosus after serologies revealed a positive antinuclear antibody test (1:2560), and antibodies to Ro/SSA and dsDNA. Hydroxychloroquine (400 mg/day) was prescribed and the patient developed severe drug-induced liver injury. Read More

    Successful treatment of severe subacute cutaneous lupus erythematosus with rituximab in an adolescent.
    Pediatr Dermatol 2018 May 23;35(3):e189-e190. Epub 2018 Mar 23.
    Department of Dermatology, University of Minnesota, Minneapolis, MN, USA.
    Subacute cutaneous lupus erythematosus is rare in children. Most patients respond well to conventional therapy with prednisone, hydroxychloroquine, or both. Other case reports and small series have reported successful clearance with rituximab in adults. Read More

    Subacute cutaneous lupus erythematosus presenting in twins.
    Pediatr Dermatol 2018 Mar 13;35(2):e128-e131. Epub 2018 Feb 13.
    Division of Pediatric Dermatology, Department of Dermatology, College of Medicine, University of Florida, Gainesville, FL, USA.
    Subacute cutaneous lupus erythematosus is a clinically distinct form of cutaneous lupus erythematosus, with age of onset typically in the second to fifth decades. Eleven cases have been reported in childhood, and we present the first known case of subacute cutaneous lupus erythematosus in identical twins. Although flares are typically photo-induced, we present an annular eruption typical of subacute cutaneous lupus erythematosus with concurrent pinworm infestation, with recurrence of disease with cutaneous larva migrans. Read More

    Drug-induced Rowell syndrome, a rare and difficult to manage disease: A case report.
    Exp Ther Med 2018 Jan 23;15(1):785-788. Epub 2017 Nov 23.
    Department of Ophthalmology, Grigore T. Popa University of Medicine and Pharmacy, 700715 Iași, Romania.
    Rowell syndrome is defined as the association between lupus erythematosus, erythema multiforme-like lesions and characteristic immunological changes including positive tests for rheumatoid factor, speckled antinuclear antibody, positive anti-Ro or anti-La antibodies. The present report presents the case of a 45-year-old female patient who was previously diagnosed in January 2010 with terbinafine-induced subacute cutaneous lupus erythematosus and was admitted for a skin eruption consisting of erythematous-papular erythema multiforme-like lesions, primarily on the trunk and limbs. The associated symptoms consisted of fatigability, myalgia and gonalgia. Read More

    Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea.
    J Dermatol 2018 Apr 9;45(4):436-443. Epub 2018 Feb 9.
    Department of Dermatology, College of Medicine, University of Hanyang, Seoul, Korea.
    An understanding of the differences in clinical manifestations and laboratory abnormalities between subtypes of cutaneous lupus erythematosus (CLE) is still lacking. The purpose of this study was to analyze demographic, clinical and histological features of CLE according to three main presentation subsets: acute (ACLE), subacute (SCLE) and chronic (CCLE). A 10-year retrospective analysis was performed on data from patients who were diagnosed with CLE between March 2005 and September 2015 in a Korean tertiary referral dermatology clinic. Read More

    The use of SLICC and ACR criteria to correctly label patients with cutaneous lupus and systemic lupus erythematosus.
    Clin Rheumatol 2018 Mar 1;37(3):817-818. Epub 2018 Feb 1.
    Dermatology Department, St. James's Hospital, Dublin, Ireland.
    The American College of Rheumatology (ACR) classification criteria for lupus and Systemic Lupus International Collaborating Clinics (SLICC) criteria are designed to classify disease. However, they have become widely used as diagnostic criteria in clinical situations. Patients may be labelled as systemic lupus erythematosus (SLE) in their medical records, when in fact they have cutaneous lupus erythematosus (CLE) without systemic symptoms. Read More

    Cutaneous lupus erythematosus: clinico-pathologic correlation.
    G Ital Dermatol Venereol 2018 Apr 24;153(2):216-229. Epub 2018 Jan 24.
    Unit of Dermatology, "A. Perrino" Hospital, Brindisi, Italy.
    Cutaneous lupus erythematosus (CLE) is a chronic-relapsing disease. It is defined as a LE localized to the skin without any significant systemic symptoms. Its annual incidence is of 4 cases per 100,000 persons with a prevalence of 73 cases per 100,000 persons. Read More

    Bullous Pemphigoid Masquerading as Erythema Annulare Centrifugum.
    Acta Dermatovenerol Croat 2017 Oct;25(3):255-256
    Sheng-Yiao Lin, No. 100, Tzyou 1st Road, Kaohsiung 807, Taiwan;
    Dear Editor, Bullous pemphigoid (BP), a relatively common autoimmune blistering disease in the elderly, is characterized by large, tense bullae on urticarial, erythematous, or normal skin. However, atypical BP with polymorphic clinical presentations is rarely encountered, leading to misdiagnosis and delayed treatments (1). BP with lesions resembling erythema gyratum repens or figurate erythema has been regarded as a paraneoplastic phenomenon (1). Read More

    [Esomeprazol-induced cutaneous lupus erythematosus].
    Z Gastroenterol 2017 Sep 12;55(9):861-865. Epub 2017 Sep 12.
    Klinik für Gastroenterologie und gastrointestinale Onkologie, Georg-August-Universität Göttingen Universitätsmedizin, Göttingen, Germany.
    Proton pump inhibitors are among the most commonly used drugs worldwide. They are considered to be largely safe and cause little side-effects. We report a 69-year-old woman who suffered from erythematous plaques 2 months after initiating therapy with esomeprazole. Read More

    [Secukinumab-induced subacute-cutaneous lupus erythematosus].
    Hautarzt 2018 Jan;69(1):64-66
    Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Hufelandstr. 55, 45122, Essen, Deutschland.
    We report about a 52-year-old woman with onset of drug-induced lupus erythematosus (DILE) in sun-exposed areas, under therapy with secukinumab. Topical therapy with a steroid class 3 for 4 weeks showed substantial improvement. The systemic therapy was switched to ustekinumab. Read More

    Cutaneous Lupus: A Brief Review of Old and New Medical Therapeutic Options.
    J Investig Dermatol Symp Proc 2017 10;18(2):S64-S68
    Department of Dermatology, Virginia Commonwealth University, Richmond, Virginia, USA.
    Systemic lupus erythematosus is a chronic inflammatory condition which affects predominantly women in their 30s. It has several clinical manifestations, including skin lesions that can be classified as acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, and chronic cutaneous lupus erythematosus. A multifaceted approach to treating cutaneous lupus is advocated. Read More

    Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus.
    Lupus 2018 Apr 1;27(5):847-852. Epub 2017 Sep 1.
    4 University Hospital of North Durham, Department of Dermatology, North Road Durham, DH1 5TW, Institute of Cellular Medicine, 5994 Newcastle University , UK.
    Background Hydroxychloroquine (HCQ), a 4-aminoquinolone antimalarial, is regarded as the oral therapy of choice for cutaneous and systemic lupus erythematosus (SLE). It is also licensed for rheumatoid arthritis (RA). Studies of HCQ-treated patients with SLE or RA have demonstrated a positive correlation between whole-blood HCQ levels and clinical response. Read More

    Severely Crusted Cheilitis as an Initial Presentation of Systemic Lupus Erythematosus.
    Indian J Dermatol 2017 Jul-Aug;62(4):440
    National Skin Centre, Department of Dermatology, Singapore.
    Lupus erythematosus (LE) is an autoimmune disease which may initially present solely with lip lesions. Due to a wide spectrum of presentation, these features may initially be misdiagnosed as other oral diseases such as lichen planus, erythema multiforme (EM), and actinic cheilitis, leading to a delay in diagnosis and treatment. We discuss a case of severely crusted cheilitis which was initially diagnosed as EM, with subsequent development of subacute cutaneous LE, and progression to systemic LE. Read More

    Systemic lupus erythematosus, following prodromal idiopathic thrombocytopenic purpura, presenting with skin lesions resembling malignant atrophic papulosis.
    Clin Exp Dermatol 2017 Oct 10;42(7):774-776. Epub 2017 Jul 10.
    Department of Dermatology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK.
    Systemic lupus erythematosus (SLE) is an autoimmune disease. Its incidence in the UK is approximately 1 per 10 000. Cutaneous involvement, encompassing acute, subacute and chronic disease, occurs in over two-thirds of cases, and can often be the first clue to diagnosis. Read More

    Ultraviolet-A1 irradiation therapy for systemic lupus erythematosus.
    Lupus 2017 Oct 8;26(12):1239-1251. Epub 2017 May 8.
    Veterans Administration, New Orleans, LA, USA.
    Systemic lupus erythematosus (lupus, SLE) is a chronic autoimmune disease characterized by the production of autoantibodies, which bind to antigens and are deposited within tissues to fix complement, resulting in widespread systemic inflammation. The studies presented herein are consistent with hyperpolarized, adenosine triphosphate (ATP)-deficient mitochondria being central to the disease process. These hyperpolarized mitochondria resist the depolarization required for activation-induced apoptosis. Read More

    Development of new extra-glandular manifestations or associated auto-immune diseases after establishing the diagnosis of primary Sjögren's syndrome : A long-term study of the Antonius Nieuwegein Sjögren (ANS) cohort.
    Rheumatol Int 2017 Jul 19;37(7):1153-1158. Epub 2017 Apr 19.
    Department of Clinical Epidemiology and Medical Statistics, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.
    To investigate in a long-term study, the development of new extra-glandular manifestations (EGM) or associated auto-immune diseases (AID) from 1 year after establishing the diagnosis of primary Sjögren's syndrome (pSS). The primary goal was to examine the frequency and type of these manifestations and to find out which demographic, clinical and serological profile was most at risk. All outpatients diagnosed with primary Sjögren's syndrome were included in a retrospective study, with at least one check-up per year, from June 1991 until August 2015. Read More

    Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus.
    Lupus Sci Med 2017 17;4(1):e000176. Epub 2017 Mar 17.
    Department of Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
    Objective: SLE is traditionally classified using the American College of Rheumatology (ACR) criteria. The Systemic Lupus International Collaborating Clinics (SLICC) recently validated an alternative system. This study examined large cohorts of subjects with SLE and incomplete lupus erythematosus (ILE) to compare the impact of ACR and SLICC criteria. Read More

    Topical drug-induced subacute cutaneous lupus erythematosus isolated to the hands.
    Lupus Sci Med 2017 13;4(1):e000207. Epub 2017 Mar 13.
    The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA; Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, New York, USA.
    Subacute cutaneous lupus erythematosus (SCLE) is a well-defined subtype of lupus erythematosus, characterised by photosensitivity, annular and/or psoriasiform lesions, variable systemic involvement and presence of circulating SSA/anti-Ro antibodies. SCLE may be idiopathic or drug-induced. Both the idiopathic and drug-induced forms of SCLE are analogous in their clinical, serological and histological features. Read More

    An update in drug-induced subacute cutaneous lupus erythematosus.
    Dermatol Online J 2017 Mar 15;23(3). Epub 2017 Mar 15.
    Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah.
    Background: It has been over three decades sincethe first report of drug-induced subacute cutaneouslupus erythematosus (DI-SCLE) was described. Withan increasing variety of implicated drugs and thepotential for publication bias, we must consider: 1) hasthere been a change in drugs most often reported inDI-SCLE over time, and, 2) if so, of which drugs shouldclinicians be most suspicious in the setting of possibleDI-SCLE?

    Objective: To determine which drug(s) present thehighest risk for inducing DI-SCLE.

    Methods: The PubMed database was queried forreports of DI-SCLE from August, 2009 until May,2016. Read More

    [A new case of Rowell's syndrome].
    Ann Dermatol Venereol 2017 Apr 18;144(4):263-267. Epub 2017 Mar 18.
    Service de dermatologie, hôpital Pasteur, 39, avenue de la Liberté, 68024 Colmar, France.
    Introduction: This article introduces a new case of Rowell's syndrome, a controversial entity defined by the association of lupus erythematosus and erythema multiforme.

    Observation: A 43-year-old woman was diagnosed with lupus erythematosus induced by esomeprazole. Because her eruption did not improve after withdrawal of the drug, hydroxychloroquine was administered. Read More

    Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review.
    J Adv Res 2016 Sep 23;7(5):719-726. Epub 2016 Apr 23.
    Department of Medical Oncology, Ioannina University Hospital, S. Niarchos Avenue, 45500 Ioannina, Greece.
    Subacute cutaneous lupus erythematosus (SCLE) is characterized by particular cutaneous manifestations such as non-scaring plaques mainly in sunlight exposed parts of the body along with specific serum autoantibodies (i.e. antinuclear antibodies (ANA), Ro/SSa, La/SSb). Read More

    Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics, Disease Associations, Treatments, and Outcomes in a Series of 90 Patients at Mayo Clinic, 1996-2011.
    Mayo Clin Proc 2017 03 6;92(3):406-414. Epub 2017 Feb 6.
    Department of Dermatology, Mayo Clinic, Rochester, MN. Electronic address:
    Objective: To characterize the clinical presentation, laboratory studies, disease associations, and treatments of subacute cutaneous lupus erythematosus (SCLE).

    Patients And Methods: A retrospective review of 90 patients with SCLE at Mayo Clinic from January 1, 1996, through October 28, 2011, was performed.

    Results: The mean patient age at diagnosis was 61 years; 64 patients (71%) were women, and 11 cases (12%) were drug induced (1996-2000, no drug-induced cases; 2001-2005, 2 cases; 2006-2011, 9 cases). Read More

    Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.
    Br J Dermatol 2017 Jul 5;177(1):188-196. Epub 2017 May 5.
    Laboratoire d'ImmunoRhumatologie Moléculaire, Service de Rhumatologie, Hôpitaux Universitaires de Strasbourg, INSERM UMR_S1109, Université de Strasbourg, Strasbourg, F-67000, France.
    Background: The antimalarials (AMs) hydroxychloroquine (HCQ) and chloroquine (CQ) have demonstrated variable cutaneous response rates in cutaneous lupus erythematosus (CLE).

    Objectives: We sought to assess the global cutaneous response rates to HCQ and CQ, with respect to CLE subtypes, based on previously published studies.

    Methods: We performed a systematic review and meta-analysis of studies published in MEDLINE, Embase and the Cochrane Library between 1965 and December 2015. Read More

    Voriconazole-Induced Subacute Cutaneous Lupus Erythematosus in an Adult With Aspergillosis.
    Skinmed 2016 1;14(6):461-463. Epub 2016 Dec 1.
    Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN.
    A 59-year-old man was treated with voriconazole for chronic invasive aspergillosis and who subsequently developed subacute cutaneous lupus erythematosus (SCLE). The patient presented with a 6-week history of multiple erythematous papulosquamous lesions on his chest, upper and lower extremities, and back (Figure 1). They were nonpruritic and nonpainful. Read More

    Rare Occurrence of Drug Induced Subacute Cutaneous Lupus Erythematosus with Leflunomide Therapy.
    J Clin Diagn Res 2016 Oct 1;10(10):OD06-OD07. Epub 2016 Oct 1.
    Intern, Department of Medicine, Pt. BD Sharma PGIMS , Rohtak, Haryana, India .
    Leflunomide is an immunomodulatory drug exhibiting anti-inflammatory, anti-proliferative and immunosuppressive effects. It has been widely used for treatment of active rheumatoid arthritis. Despite its good safety profile cutaneous side effects like alopecia, eczema, pruritis and dry skin have been reported with Leflunomide use. Read More

    Subacute cutaneous lupus erythematosus inducing unilateral sensorimotor neuropathy.
    Rheumatol Int 2017 May 25;37(5):831-835. Epub 2016 Nov 25.
    Department of Internal Medicine, Nicosia General Hospital, Nicosia, Cyprus.
    We describe the case of a 32-year-old male with previous history of subacute cutaneous lupus erythematosus (SCLE) who presented with arthritis followed by a unilateral lower-limb sensorimotor impairment, without biochemical or immunological marker abnormalities. Our patient currently satisfies only three of the systemic lupus international collaborating clinics criteria. Management of such patients is challenging due to lack of examples in the literature, with this case being the first described where a seronegative patient with SCLE demonstrated neurological involvement. Read More

    1 OF 17